Nimbus Therapeutics

Nimbus Therapeutics is a biotechnology company focused on designing small molecule therapeutics to address significant challenges in drug development. The company operates in the pharmaceutical and biotechnology market, serving patients with unmet medical needs. Nimbus employs a unique collective expertise to push the boundaries of drug discovery and development. The business model revolves around research and development of breakthrough medicines, backed by substantial investments from prominent life science investors like Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, and Lightstone Ventures. Nimbus generates revenue through partnerships, licensing agreements, and milestone payments from pharmaceutical companies. The company has secured multiple rounds of financing, including a $24 million Series A in 2011, a $43 million Series B in 2015, and an additional $65 million in 2018.

Keywords: small molecule therapeutics, drug discovery, biotechnology, pharmaceutical, life science investors, breakthrough medicines, research and development, licensing agreements, milestone payments, unmet medical needs.